XTalks

MAY 21, 2024

Initiatives like Patient Focused Drug Development meetings and patient listening sessions are instrumental in understanding the real-world impacts of living with certain diseases and the factors influencing a patient’s decision to participate in trials.

Clinical Trials 64

Clinical Trials Clinical Trials Trials Clinical Research 64

XTalks

JUNE 30, 2023

“The approval of Ultravist-300 and -370 in contrast-enhanced mammography gives physicians a new imaging option where conventional mammography might not be enough,” said Dr. Konstanze Diefenbach, head of Radiology Research and Development at Bayer, in the company’s news release. “We

FDA Approval 98

FDA Approval Radiology Trials Life Science 98

XTalks

APRIL 7, 2021

COVID-19 antibody tests can help identify people who may have had prior COVID-19 infection, and importantly, asymptomatic individuals with a developing or current infection. The tests do not detect the SARS-CoV-2 virus itself, and hence should not be used for diagnostic purposes.

Antibody 102

Antibody Immune Response Radiology Marketing 102

XTalks

MARCH 27, 2023

The antifungal drug was approved under Priority Review based on its Qualified Infection Disease Product designation , an incentive to promote development of antifungals for life-threatening infections. The Phase III results support the ongoing development of rezafungin based on efficacy and safety.

Clinical Trials 98

Clinical Trials Clinical Trials Branding Trials 98

The Pharma Data

OCTOBER 1, 2021

Dr. Olaf Weber, Head of Radiology Research and Development at Bayer. LEADER-75 underlines our commitment to developing contrast agents that provide physicians with the image enhancement required for optimal diagnosis while continuing to explore opportunities to scale back the dose for patients as best as possible.”.

Radiology 52

Radiology Life Science Development Production 52

The Pharma Data

NOVEMBER 19, 2020

Previously, she was head of Business Development at Cubist Pharmaceuticals. Previously, Baffa was Therapeutic Area Head of Oncology, Global Clinical Development for Shire. Day Zero – Dekel Gelbman was named senior vice president of Business and Development Strategy for Day Zero Diagnostics, Inc. Cogentus Pharmaceuticals, Inc.,

Life Science 52

Life Science Research Development Radiology 52

XTalks

JULY 13, 2022

Around one in three adults in the US (or about 80 million Americans) are at risk of developing CKD. “The work conducted in collaboration with the leadership at the FDA’s Center for Devices and Radiological Health facilitated the development of AI innovation that will now deliver better digital health to the American public.

Reagent 98

Reagent In-Vitro Radiology Life Science 98

XTalks

JULY 10, 2024

” The Xpert HCV test’s development was validated through the Independent Test Assessment Program (ITAP), part of the National Institutes of Health’s (NIH) Rapid Acceleration of Diagnostics (RADx) Tech program. Without treatment, over half become chronically infected, with 10 to 20 percent developing cirrhosis over 20 to 30 years.

RNA 97

RNA In-Vitro Genotype Marketing 97

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. The products encompass molecular, antigen and T cell-based testing approaches.

Protein 98

Protein RNA Antibody Production 98

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Why is it Difficult to Develop CNS Therapeutics? Intrathecal Drug Systems are an Important Pain Treatment Modality.

Trials 83

Trials Drug Delivery Drugs Gene 83

XTalks

JANUARY 19, 2024

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

MAY 13, 2022

This involves careful selection and development of packaging systems with considerations of stability, storage, accelerated aging, freeze-thaw, altitude, drop, vibration distribution simulation, as well as identification and characterization of compounds released from packaging materials (i.e. shaking, changes in pressure, etc.).

Packaging 98

Packaging Packaging Containment Production 98

pharmaphorum

MARCH 11, 2021

Estimates of medical diagnostics worth to the UK vary – MedTech Europe puts its value at around £1billion while the Office for Life Sciences reported in 2018 that it accounts for around 27% of the £24 billion turnover generated annually by the UK’s medtech sector.

In-Vitro 71

In-Vitro Containment Radiology Life Science 71

XTalks

NOVEMBER 7, 2022

In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments. During the webinar, Dr. Bahassi gave a brief schematic of how personalized, targeted assays can be developed to detect somatic mutations from cfDNA ( Figure 1 ).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Delveinsight

SEPTEMBER 2, 2021

According to DelveInsight’s Neuromodulation Devices Market Analysis , the approval of this device will drive the market growth as around seven million people in the United States are currently living with stroke-related complications, and more than 80% of stroke survivors are estimated to develop gait impairment.

Marketing 72

Marketing Radiology Drugs Drug Delivery 72

XTalks

JUNE 12, 2023

These powerhouse organizations have not only distinguished themselves through their cutting-edge devices and technologies but also via their robust research and development (R&D) capabilities, unwavering commitment to quality and extensive global reach. The company reported an investment of $2.7

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

The Pharma Data

DECEMBER 23, 2020

Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA). It will be funded by the U.S. Department of Defense.

DNA 40

DNA Vaccination Vaccine Immune Response 40

Intouch Solutions

SEPTEMBER 27, 2024

The discourse wasn’t just about cycling through tissue or aiding clinical development; it ranged from mutation prediction to tumor microenvironment (TME) analysis to how AI can aid in diagnosis and treatment planning to achieve better outcomes for patients. Hi, I am Barry Vuscko, SVP of Strategic Development.

DNA 59

DNA Trials Antibody Marketing 59

pharmaphorum

MARCH 16, 2021

The use of real-world evidence is proving beneficial for pharma and medical devices companies across the lifecycle of development from R&D to re-purposing. There are a good number of use cases as to why pretty much every big life science company is choosing us these days,” says Medrano. AI use in the pandemic. About Savana.

Doctor 116

Doctor Doctors Life Science Clinical Research 116

XTalks

SEPTEMBER 11, 2024

Jansen recently moderated a webinar in which her colleagues at Medpace discussed the evolving women’s health sector, including the historical challenges and emerging trends in clinical development. The evolving focus in women’s health aims to address these gaps by also prioritizing conditions that primarily affect quality of life.

Clinical Trials 103

Clinical Trials Clinical Trials Trials Hormones 103

XTalks

SEPTEMBER 14, 2020

And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. The company is also in collaboration with Ridgeback Biotherapeutics to develop a novel oral antiviral treatment for COVID-19. helped protect COVID-19 patients against developing severe disease.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92